Actuate Therapeutics Inc's Comment on Sales, Marketing and Customers
The company operates within a regulatory environment characterized by extensive governmental oversight of drug pricing and reimbursement. U.S. Congressional inquiries and federal and state legislation focus on transparency in drug pricing, reduction of Medicare drug costs, and reform of reimbursement methodologies. The FDA and the Department of Health and Human Services (HHS) have issued rules affecting drug importation, price reductions, and pharmacy benefit manager arrangements. State legislatures have enacted laws addressing pharmaceutical pricing controls, patient reimbursement, discounts, product access, marketing transparency, importation, and bulk purchasing. The Inflation Reduction Act of 2022 mandates HHS to negotiate prices for certain Medicare-covered drugs, penalizes price increases exceeding inflation, eliminates the Medicare Part D coverage gap, and establishes a manufacturer discount program. HHS is implementing these provisions through guidance and pilot programs aimed at lowering drug costs and improving care quality. Key customers include Medicare beneficiaries and plan sponsors under Medicare Part D.
In a significant advancement in the treatment of soft tissue sarcomas (STS), Actuate Therapeutics, Inc. a clinical-stage biopharmaceutical company, announced on September 11, 2024, that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for elraglusib, a novel glycogen synthase kinase-3 beta (GSK-3) inhibitor. This designation underscores the medical need for innovative therapies in the management of STS, a complex and heterogeneous group of malignancies with historically limited treatment options.Soft tissue sarcomas are rare tumors originating from mesenchymal tissues, affecting approximately 12,000 patients in the United States annually. The therapeutic landscape for STS...
Actuate Therapeutics Inc’s Comment on Sales, Marketing and Customers
The company operates within a regulatory environment characterized by extensive governmental oversight of drug pricing and reimbursement. U.S. Congressional inquiries and federal and state legislation focus on transparency in drug pricing, reduction of Medicare drug costs, and reform of reimbursement methodologies. The FDA and the Department of Health and Human Services (HHS) have issued rules affecting drug importation, price reductions, and pharmacy benefit manager arrangements. State legislatures have enacted laws addressing pharmaceutical pricing controls, patient reimbursement, discounts, product access, marketing transparency, importation, and bulk purchasing. The Inflation Reduction Act of 2022 mandates HHS to negotiate prices for certain Medicare-covered drugs, penalizes price increases exceeding inflation, eliminates the Medicare Part D coverage gap, and establishes a manufacturer discount program. HHS is implementing these provisions through guidance and pilot programs aimed at lowering drug costs and improving care quality. Key customers include Medicare beneficiaries and plan sponsors under Medicare Part D.
Sources:
Actuate Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Actuate Therapeutics Inc’s corporate clients.
For your research, we’ve provided 9 tables on Actuate Therapeutics Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
